ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Bypass Budget For FY99 Proposes Expansion of Cancer Clinical Trials System

December 5, 1997

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

More Bad News For Estrogen: Increased Ovarian Cancer Risk

July 19, 2002

NCI Awards $59M Contract For Key Project To consolidate Phase III Trial Administration

October 29, 1999

Kadcyla Extends Median PFS In Open-Label Phase III Trial

October 25, 2013

Drug Approvals: FDA grants accelerated approval for Keytruda in metastatic melanoma

September 5, 2014